CLEC12A and acute myeloid leukemia: In 2022, anti-CLL1 CAR-T was tested in 10 R/R AML patients with a cCR rate of 70%; furthermore, 6 patients obtained MRD-CR (transient in 4 cases), and 6 patients underwent HSCT.